

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/IL05/000303

International filing date: 17 March 2005 (17.03.2005)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/553,966
Filing date: 18 March 2004 (18.03.2004)

Date of receipt at the International Bureau: 09 June 2005 (09.06.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse

PCT/IL 2005/000303
25 MAY 2005

PA 1313208

THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office


May 02, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE UNDER 35 USC 111.

APPLICATION NUMBER: 60/553,966

FILING DATE: *March 18, 2004*

By Authority of the
COMMISSIONER OF PATENTS AND TRADEMARKS



H. L. JACKSON
Certifying Officer



13281 U.S. PTO

PTO/SB/16 (01-04)

Approved for use through 07/31/2008. OMB 0651-0032

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a PROVISIONAL APPLICATION FOR PATENT under 37 CFR 1.53(c).

Express Mail Label No.

1587 U.S. P. 60/553966

031804

INVENTOR(S)					
Given Name (first and middle [if any])		Family Name or Surname		Residence (City and either State or Foreign Country)	
ELAN		ZIV MD		RAMAT GAN, ISRAEL	
Additional inventors are being named on the _____ separately numbered sheets attached hereto					
TITLE OF THE INVENTION (500 characters max)					
A DISMANTLING SYSTEM FOR A DISABLED DEVICE FOR TREATING PELVIC ORGAN PROLAPSE					
Direct all correspondence to: CORRESPONDENCE ADDRESS					
<input type="checkbox"/> Customer Number: _____					
OR					
<input type="checkbox"/> Firm or Individual Name		ELAN ZIV MD			
Address		8 HAILANOT ST			
Address					
City		RAMAT GAN		State	Zip
Country		ISRAEL		Telephone	Fax
				+972-5356424	+972-3-7769263
ENCLOSED APPLICATION PARTS (check all that apply)					
<input checked="" type="checkbox"/> Specification Number of Pages		7		<input type="checkbox"/> CD(s), Number _____	
<input checked="" type="checkbox"/> Drawing(s) Number of Sheets		3		<input type="checkbox"/> Other (specify) _____	
<input checked="" type="checkbox"/> Application Data Sheet. See 37 CFR 1.76					
METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT					
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27.				FILING FEE Amount (\$)	
<input checked="" type="checkbox"/> A check or money order is enclosed to cover the filing fees.				<div style="border: 1px solid black; padding: 10px; text-align: center;">\$80</div>	
<input type="checkbox"/> The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: _____					
<input type="checkbox"/> Payment by credit card. Form PTO-2038 is attached.					
The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.					
<input checked="" type="checkbox"/> No.					
<input type="checkbox"/> Yes, the name of the U.S. Government agency and the Government contract number are: _____					

[Page 1 of 2]

Respectfully submitted,

SIGNATURE

TYPED or PRINTED NAME

TELEPHONE

EL

Dr. ELAN ZIV MD

+972-53-56928

Date

15.2.04

REGISTRATION NO.

(if appropriate)

Docket Number:

USE ONLY FOR FILING A PROVISIONAL APPLICATION FOR PATENT

This collection of information is required by 37 CFR 1.51. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 8 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Mail Stop Provisional Application, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2

1328-1
U.S. PTO
FEE TRANSMITTAL
for FY 2004

Effective 10/01/2003. Patent fees are subject to annual revision.

☒ Applicant claims small entity status. See 37 CFR 1.27

TOTAL AMOUNT OF PAYMENT (\$) 80

Complete if Known

Application Number	
Filing Date	MARCH 15, 2004
First Named Inventor	Dr Elan Ziv
Examiner Name	
Art Unit	
Attorney Docket No.	

METHOD OF PAYMENT (check all that apply)

☐ Check ☐ Credit card ☒ Money Order ☐ Other ☐ None

☐ Deposit Account:

Deposit Account Number
Deposit Account Name

The Director is authorized to: (check all that apply)

☐ Charge fee(s) indicated below ☐ Credit any overpayments
☐ Charge any additional fee(s) or any underpayment of fee(s)
☐ Charge fee(s) indicated below, except for the filing fee to the above-identified deposit account.

FEE CALCULATION

1. BASIC FILING FEE

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1001 770	2001 385	Utility filing fee	
1002 340	2002 170	Design filing fee	
1003 530	2003 265	Plant filing fee	
1004 770	2004 385	Reissue filing fee	
1005 160	2005 80	Provisional filing fee	80
SUBTOTAL (1)			(\$) 80

2. EXTRA CLAIM FEES FOR UTILITY AND REISSUE

Total Claims -20** = X =
Independent Claims -3** = X =
Multiple Dependent =

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description
1202 18	2202 9	Claims in excess of 20
1201 86	2201 43	Independent claims in excess of 3
1203 290	2203 145	Multiple dependent claim, if not paid
1204 86	2204 43	** Reissue independent claims over original patent
1205 18	2205 9	** Reissue claims in excess of 20 and over original patent

SUBTOTAL (2) (\$)

**or number previously paid, if greater; For Reissues, see above

FEE CALCULATION (continued)

3. ADDITIONAL FEES

Large Entity Fee Code (\$)	Small Entity Fee Code (\$)	Fee Description	Fee Paid
1051 130	2051 65	Surcharge - late filing fee or oath	
1052 50	2052 25	Surcharge - late provisional filing fee or cover sheet	
1053 130	1053 130	Non-English specification	
1812 2,520	1812 2,520	For filing a request for ex parte reexamination	
1804 920*	1804 920*	Requesting publication of SIR prior to Examiner action	
1805 1,840*	1805 1,840*	Requesting publication of SIR after Examiner action	
1251 110	2251 55	Extension for reply within first month	
1252 420	2252 210	Extension for reply within second month	
1253 950	2253 475	Extension for reply within third month	
1254 1,480	2254 740	Extension for reply within fourth month	
1255 2,010	2255 1,005	Extension for reply within fifth month	
1401 330	2401 165	Notice of Appeal	
1402 330	2402 165	Filing a brief in support of an appeal	
1403 290	2403 145	Request for oral hearing	
1451 1,510	1451 1,510	Petition to institute a public use proceeding	
1452 110	2452 55	Petition to revive - unavoidable	
1453 1,330	2453 665	Petition to revive - unintentional	
1501 1,330	2501 665	Utility issue fee (or reissue)	
1502 480	2502 240	Design issue fee	
1503 640	2503 320	Plant issue fee	
1460 130	1460 130	Petitions to the Commissioner	
1807 50	1807 50	Processing fee under 37 CFR 1.17(q)	
1806 180	1806 180	Submission of Information Disclosure Stmt	
8021 40	8021 40	Recording each patent assignment per property (times number of properties)	
1809 770	2809 385	Filing a submission after final rejection (37 CFR 1.129(a))	
1810 770	2810 385	For each additional invention to be examined (37 CFR 1.129(b))	
1801 770	2801 385	Request for Continued Examination (RCE)	
1802 900	1802 900	Request for expedited examination of a design application	

Other fee (specify) _____

*Reduced by Basic Filing Fee Paid

SUBTOTAL (3) (\$)

SUBMITTED BY

Name (Print/Type) Dr Elan Ziv MD
Signature *[Signature]*

Registration No.
(Attorney/Agent)

Telephone +97237369261

Date March 14, 2004

WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.

This collection of information is required by 37 CFR 1.17 and 1.27. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.
SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9189 and select option 2.

A DISMANTLING SYSTEM FOR A DISPOSABLE DEVICE FOR TREATING PELVIC ORGAN PROLAPSE.

The present invention relates generally to the field of treatment and prevention of pelvic organ prolapse in female patients. Specifically, the invention describes a dismantling system of a vaginal disposable device which is inserted into the vagina by the patient herself, allowing for an easy removal of the device.

10 **Inventor:** Dr Elan Ziv, MD OBGYN, Urogynecologist

Background of the Invention

15 Pelvic organ prolapse is defined as a condition in which vaginal wall support is lost, and various pelvic organs prolapse into the vagina. This is a very bothering condition, though in most cases it is not a dangerous one. It might appear alone or in combination with urinary stress incontinence.

POP (Pelvic Organ Prolapse) is a very common condition in females, in which various organs, surrounding the vagina, prolapse into it. The reasons for such prolapse are numerous, mainly because the vagina has a very low tensile strength within its walls due to damage to muscles, nerves, fascias etc. There might also be a change within the collagen content, thereby causing a weaker pelvic floor. According to the older definition, prolapse may be divided into five categories, according to the organ that is sagging down (urethra, bladder, uterus, rectum and the pouch of Douglas (small bowl)), and to three grades according to the amount of descent (within the vagina, at the entrance to the vagina, protruding out of the vagina). There might be a combination of various organs prolapse at the same time, with different level of descent. The newer classification (POP-Q) takes into account other factors, such as location of the prolapse and the distance from the entrance of the vagina. There is very little data regarding the prevalence of the problem but it seems to be age related, and older women have much higher tendency towards developing some form of pelvic organ prolapse.

Current treatment

At present – there are 2 ways of dealing with Pelvic Organ Prolapses:

1. Surgical – vaginal or abdominal
2. Use of vaginal devices (pessaries) that are inserted into the vagina and
5 mechanically reduce the prolapse by pushing the wall aside and upwards.

Efforts to avoid surgical procedures have resulted in the development of a number of non-surgical vaginal devices, inserted into the vagina by the surgeon or the patient.

Vaginal devices are well known for their tremendous diversity in shapes and sizes. These devices are meant to prevent prolapse of the vaginal walls, with different location
10 of pressure application.

Some of these devices tend to block all flow of urine from the bladder. Therefore, when a patient needs to urinate, the device must be removed from the vagina or must be collapsed to remove the pressure applied against the bladder neck. Trying to solve this problem, vaginal devices were developed in special shapes, without completely
15 blocking the bladder neck so that the patient may urinate with the device in place. These devices, however, are generally large and intrusive and, therefore, are uncomfortable to wear, with low patient satisfaction and compliance. They are also relatively expensive, and therefore designed to be reusable.

20 There are several drawbacks of existing vaginal devices:

1. Most of them are intended to be reusable, hence they are made as resilient large bodies, made of plastic, hard rubber, or other such materials, in order to preserve their shape and function for a long time.
2. Insertion of large noncompliant bodies is sometimes difficult, painful or
25 unpleasant, sometimes necessitating a medical practitioner.
3. Removal causes same unpleasantness, sometimes even more than insertion. The patient or the medical practitioners have to insert a finger into the vagina in order to "hook" the device and pull it out without the ability to reduce its dimensions for a more comfortable passage. In order to avoid insertion of a
30 finger, a hook like extractor was developed (US patent D404127) was developed but has never been in use.

4. Most reusable devices are meant to remain in the vagina for prolonged periods of time, thereby causing irritations, pressure ulcers, infections, foul smelling discharge, etc.
5. Such reusable devices have a long standing bad reputation among patients and medical practitioners for being unpleasant, causing infectious discharge and foul odor, and being associated with disability and old age.
6. Some reusable devices are meant to be inserted daily by the patient, and to be removed after several hours, by means of pulling a string or with a finger, to be cleaned for re-use, and to be kept in certain conditions prior to following insertion. Some patients are reluctant to touch their selves in such intimate parts of their bodies, or disgusted to clean the device, hence their reluctance to use it.

Vaginal devices may cause three main side effects:

1. **Infections**-any foreign material, anywhere in the body, may become infected by several kinds of organisms, and cause formation of a foul smelly discharge. Reusable devices are certainly prone to cause such infections, but also, less frequently, disposable ones. In order to prevent such infections, devices should be:

- disposable
- used for a limited length of time, in order to prevent organism from growing, and to prevent damage, by vascular pressure, to the vaginal wall.
- made in a way that will allow vaginal or cervical normal secretions to flow out of the body
- made of certain known materials that would not permit growth of organisms.

2. **Toxic Shock Syndrome (TSS)** is a condition, described some years ago, in which abundant growth of *Staphylococcus Aureus*, a bacteria that utilizes the cellulose within sanitary menstrual tampons, released large amounts of toxin. That toxin caused a collapse of vital body systems, forming a dangerous condition. In order to overcome this, sanitary tampons do not contain cellulose anymore, and vaginal devices, as described earlier, should be made of materials that would not permit the growth of bacteria, and allow for discharge flow. This is best done by using properly made disposable devices.

3. **Pressure Necrosis** – prolonged pressure on the vaginal sidewalls may cause pressure on blood vessels with resultant necrosis, bleeding and infections. This might be prevented by using disposable devices only, for a predetermined length of time.

5

The invention

This dismantling device was developed following the invention of a previous device, intended to be inserted into the vagina with an applicator. The device is intended to be applied into the vagina with an applicator much like the insertion of a regular menstrual tampon .After insertion, the device should expand significantly to the predefined shape and size, thereby exerting predefined appropriate pressure on both lateral vaginal walls, pushing them aside. The apex of the vagina shall be pushed upwards at the same time. That expansion of the device shall eventually create linear stretching of the anterior & posterior vaginal walls, while creating a new shape of intra-vaginal hollow (rectangle).

10 The device may be left inside the vagina for several hours. Removal for disposal will occur while pulling a string and collapsing the device to a much smaller size.

As with other devices of the prior art, this device has a ring or rectangular shape. Removal of such a large body through a small dimension vaginal introitus might be extremely painful and uncomfortable, hence the need for designing such a specific dismantling system.

15 This new inventions brings about a system for collapsing a large body into a much smaller one which will allow its immediate removal.

The invention will now be described with reference to accompanying drawings:

- 20
- FIG.1A is a front view of the dismantling system in the device.
 - FIG.1B is a side view of the dismantling system in the device.
 - FIG.1C is a perspective view of the dismantling system in the device.
 - FIG.2A is a front view of the open dismantling system in the device.
 - FIG.2B is a side view of the open dismantling system in the device.
- 25
- FIG.2C is a perspective view of the open dismantling system in the device.
 - FIG.3 is a front view of the conic shape of the device when the collapse system pulls it out.

The dismantling system has two phases:

- 30
- Closed (FIG 1)
 - Opened (FIG 2)

Figures 1A+1B+1C show the device in its front, side & perspective views. A small dismantling ring (6,14) is attached in a 90 degrees fashion to the main body of the

device (10,13), within two collapsing sites (18L, 18R), which are small indentation located on its inner surface, close to its lowest margin. These two indented sites enable to contain the dismantling ring without harming the devices integrity and strength. Removal string (12, 16) is attached to the dismantling ring. Connecting string (8) statically connects between the device (13) and the dismantling ring (14). Since the dismantling ring is located within the indentation, the mechanical strength of the device remains unchanged, and its intended task is fulfilled. This phase remains as long as there is no pull of the string.

Figures 2A+2B+2C show the beginning of the opened phase – the system after first pull of the string as a first step in removal of the device from the vagina. When string (16) is pulled, the dismantling ring (14) is moved away from its two indented sites (18R, 18L), and hangs away from the device itself, connected to it by the connecting string (20), in a lower position within the vagina.

FIG 3 shows a more advanced pull of the string. At this stage, the two indentation sites (22) collapse as a result of lower strength and the device becomes narrow in its lower part (conical), thereby allowing for comfortable and easy removal (still as one unit) from the vagina, for disposal.




The invention has in its basic concept the following features:

- Being a disposable device.
- Easy & comfortable removal.
- Being comfortable to wear.
- 5 • Being hygiene & odorless
- Being a familiar procedure to most female patients – as inserting a menstrual tampon.
- Being removed by the patient herself, in a no-self-touch technique, with the device collapsing and becoming of small size for painless removal.
- 10 • Being of high availability, easy to get everywhere, sold as an Over the Counter (OTC) device.
- Being of low cost.
- Having complete confidentiality, as with the use of menstrual tampons.
- Having the ability to be removed instantly when needed.
- 15 • The system does not influence performance of the device itself.
- The system helps anchoring the device within the vagina.
- The device is removed as one unit and does not require division.

Alternative embodiments of the invention.

- 20 • Dismantling rings may be manufactured in different sizes
- Dismantling rings may be manufactured in different strengths
- It may be made of many flexible materials, such as plastics, cardboard, etc.
- Collapsing indentations may be added to the device.
- Collapsing indentation sites may be changed.




25



BEST AVAILABLE COPY


BEST AVAILABLE COPY

"A dismantling system for a disposable device for treating pelvic organ prolapse"
 Dr Elan Ziv, MD OBGYN, Urogynecologist



"A dismantling system for a disposable device for treating pelvic organ prolapse"
Dr Elan Ziv, MD OBGYN, Urogynecologist

BEST AVAILABLE COPY



"A dismantling system for a disposable device for treating pelvic organ prolapse"
 Dr Elan Ziv, MD OBGYN, Urogynecologist

BEST AVAILABLE COPY